Among others, SAM Holdings will help EnGeneIC secure funding and regulatory authorisations for building a manufacturing plant in Singapore to manufacture EDV-based products and conduct clinical trials in the city-state. In turn, SAM Holdings will be granted exclusive distribution and marketing rights of these products in 17 countries within Asia.
SAM Holdings will also collaborate with EnGeneIC for pre-clinical testing of EDV-based theranostics as well as obtain the regulatory approval for its commercialisation and sale. Subsequently, the company will be granted exclusive distribution rights worldwide for EDV-based theranostics.
“We have always been committed to providing our patients with easier access to the latest cancer treatment technologies and our partnership with EnGeneIC is another step forward in that direction,” says SAM Holdings executive director, CEO and founder Dr Djeng Shih Kien.
Shares in SAM Holdings closed 0.8 cents lower or 6.78% down on June 10 at 11 cents.
See also: Sembcorp signs JV agreement with BPCL for green hydrogen transition and renewable energy in India
